HCA Healthcare stock jumps on upbeat 2026 outlook, $10B buyback as ACA subsidy cliff looms
27 January 2026
1 min read

HCA Healthcare stock jumps on upbeat 2026 outlook, $10B buyback as ACA subsidy cliff looms

New York, January 27, 2026, 13:29 EST — Regular session

HCA Healthcare shares surged Tuesday following an upgrade to its 2026 profit forecast and the announcement of a fresh $10 billion share buyback plan. The stock was last trading 7.4% higher at $507.50, hitting gains as steep as 11.7% earlier in the day.

This shift is crucial as hospital operators face a coverage reset year. Investors want to understand how volumes and unpaid bills might change if fewer patients have insurance, and if large systems can trim costs enough to preserve their margins.

HCA plans to counter the impact of expiring Affordable Care Act subsidies with roughly $400 million in cost cuts, Reuters reported. CFO Mike Marks noted the company expects a roughly 30% drop in utilization among patients losing coverage. He added, “We have planned elements to drive better capacity management,” including efforts to improve patient flow and reduce length of stay. The company is also banking on analytics, AI, and automation to hit its savings targets. Reuters

HCA reported a 6.7% jump in fourth-quarter revenue to $19.513 billion, with adjusted earnings hitting $8.01 per share. Same-facility equivalent admissions, combining inpatient and outpatient volume, rose 2.5%. Adjusted EBITDA climbed to $4.114 billion, reflecting stronger operating profit. CEO Sam Hazen described the 2025 finish as “strong.” Looking ahead, the company projects 2026 revenue between $76.5 billion and $80.0 billion, with earnings per share expected in the $29.10 to $31.50 range. HCA Healthcare

HCA disclosed in an SEC filing that its board has approved a new share buyback program, allowing repurchases of up to $10 billion. The company also declared a quarterly cash dividend of $0.78 per share, set for payment on March 31 to shareholders on record as of March 17.

Peers showed mixed moves. Tenet Healthcare climbed around 1.4%, but Universal Health Services dropped close to 0.7%, and Community Health Systems slid about 2.2% by midday.

Investors will push for clarity on when the cost-savings plan starts impacting results and if HCA can maintain admissions growth amid shrinking exchange coverage. The speed of buybacks will also be closely watched, particularly as rates remain elevated and debt markets grow less accommodating.

Earnings for the quarter appeared solid, yet volume trends showed inconsistencies across the system. Outpatient activity, especially, will draw attention as payers continue shifting care from hospitals to lower-cost venues.

The risk is clear: if the subsidy phase-out causes uninsured patient numbers to spike faster than HCA anticipates, uncompensated care—unpaid treatment—might increase, squeezing margins. Cost-cutting efforts could also fall short if wage inflation intensifies or throughput improvements hit a snag.

Next, investors will focus on management’s update regarding the coverage shift and the $400 million savings goal. The dividend timeline provides a short-term checkpoint, keyed to the March 17 record date and the payout scheduled for March 31.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • XBI Tops PBE in Biotech ETF Returns, Strategies Diverge on Risk and Fees
    July 24, 2026, 9:07 AM EDT. The SPDR S&P Biotech ETF (XBI) delivered a 73% return in one year, significantly ahead of the Invesco Biotechnology & Genome ETF (PBE)'s 35% gain, boosted by XBI's equal weighting of more than 100 biotech stocks and its lower 0.35% expense ratio versus PBE's 0.58%. During the 2021-2022 sector slump, however, PBE's focus on quality and large-cap stocks resulted in five-year returns that matched XBI's 20% but with reduced volatility, underscoring the differences in their investment approaches.
Intuitive Surgical stock price: what to watch Monday after ISRG’s 2026 da Vinci outlook and tariffs hit focus
Previous Story

Intuitive Surgical stock price: what to watch Monday after ISRG’s 2026 da Vinci outlook and tariffs hit focus

Lumen Technologies (LUMN) stock jumps on ISO 42001 AI certification as earnings loom
Next Story

Lumen Technologies (LUMN) stock jumps on ISO 42001 AI certification as earnings loom